Make an appointment Confirm/change/cancel appt Find a location


Home  About Us  Site Directory  Privacy Policy  
Company InfoOur BusinessesInvestor RelationsCareersContact Us
Newsroom
Newsroom Home
Press Releases
Media Contacts
Media Coverage
Company Information
Senior Leadership
Company History
Rankings and Reputation
Investor Relations
Sign up to receive Quest Diagnostics News Alerts
QuestCares Corporate Social Responsibility
Press Releases

This section of the website contains information that should be considered accurate as of the date presented. You acknowledge that this information may change over time and you should not assume that the information is accurate at a later date. Quest Diagnostics is not obligated to update the information contained in this section of the website.

Archives: Search / 2010 / 2009 / 2008 / 2007 / 2006 / 2005 / 2004 / 2003 / 2002 / 2001

Aug 23, 2010
Quest Diagnostics' Care360™ EHR Module Receives Preliminary ARRA IFR Stage 1 Certification
Aug 11, 2010
Quest Diagnostics Declares Quarterly Cash Dividend
Jul 28, 2010
New York State Approves Quest Diagnostics' Fragile X Syndrome Test
XSense® is the first laboratory test that may be suitable for population-based screening for Fragile X Syndrome, the leading inherited cause of mental retardation
Jul 21, 2010
Quest Diagnostics Reports Second Quarter 2010 Financial Results; Updates Guidance for 2010
- Diluted earnings per share of $1.07, 7% above 2009
Jul 14, 2010
Quest Diagnostics To Release Second Quarter 2010 Financial Results
 

 Email Page    Print
Go to: HOME | Healthcare Professionals | Patients and Consumers | About Our Company

Quest, Quest Diagnostics, the associated logo, Nichols Institute and all associated Quest Diagnostics marks are the registered trademarks of Quest Diagnostics. All third party marks — ®' and ™' — are the property of their respective owners. © 2000-2009 Quest Diagnostics Incorporated. All rights reserved.